Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Chemmedchem|April 4, 2017
Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2Matias Casás-Selves, Andrew X Zhang, James E Dowling, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 20, 2019
Improving HIV Surveillance Data by Using the ATra Black Box System to Assist Regional Deduplication ActivitiesJoanne Michelle F Ocampo, Auntré Hamp, Anne Rhodes, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights from Comprehensive Multicenter Preclinical StudiesSarah-Eve Lemay, Monica S Montesinos, Yann Grobs, et al.
Circulation|January 20, 2025
Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical StudiesSarah-Eve Lemay, Mónica S Montesinos, Yann Grobs, et al.
Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Journal of Medicinal Chemistry|October 24, 2024
The Discovery of MORF-627, a Highly Selective Conformationally-Biased Zwitterionic Integrin αvβ6 Inhibitor for FibrosisBryce A Harrison, James E Dowling, Matthew G Bursavich, et al.
Pageof 2